الفهرس 
Short course versus standard course of radiotherapy in glioblastoma multiforme
ContentsOnly 14 pages are availabe for public view
 |  | from | 148 |  |  |
| | | from | 148 | | |
Abstract
To perform a subset analysis of survival outcomes in patients with glioblastoma (GBM) from a randomized trial comparing short-course radiotherapy (RT) regimens with standard course. Methods and Materials Patients joined the randomized, multicenter, prospective trial and were assigned to one of two groups in a 1:1 ratio to either short-course RT (40 Gy in 15 fractions, arm 1) or standard course RT (60 Gy in 30 fractions, arm 2) with concurrent temozolomide and adjuvant temozolomide for 6 months. patients were stratified by Age, performance status, and extent of surgery. Results In this analysis, the short-course RT results were not statistically significant different to standard course RT. The median overall survival time was 13.7months (95% CI, 4.5 to 9.1 months) in arm 1 and 15 months (95% CI, 8.5 to 22.0 months) in arm 2 (P = 0.936). Median progression-free survival time was 12 months (95% CI: 8.2-15.7) in arm 1 and 12.8 months (95% CI: 7.96-17.63) in arm 2 (P = 0.706). Conclusions A short-course RT regimen of 40 Gy in 15 fractions is an acceptable treatment option for patients with glioblastomamultiforme, in order to reduce cost and the machine overload in view of non-significant difference in survival, toxicity and response rate compared to standard course